SuspendedNot applicableNCT00280189

Study of Outcomes of Radiofrequency Ablation of Lung Tumors

The purpose of this study is to assess short and long term outcomes after radiofrequency ablation (RFA) of pulmonary malignancies in patients who are not candidates for surgical resection. This study will evaluate the efficacy of RFA for the treatment of lung tumors by assessing its impact on local tumor control, progression free survival, overall survival, dyspnea score and quality of life (QOL).

Checked against the public recordLast updated Apr 14, 2026 · Source: ClinicalTrials.gov

StatusSuspended
PhaseNot applicable
U.S. locations1
SponsorUniversity of Pittsburgh
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
University of Pittsburgh
Interventions being studied
Procedure: Radiofrequency ablation of pulmonary malignancies; Behavioral: Quality of life assessment; Behavioral: Assessment of pain
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Have stage I or II primary lung cancer and who are felt not to be candidates for resection based upon co-morbid disease or who refuse lung resection. * Have metastatic tumors to the lung, and who meet criteria for metastasectomy but who are felt not to be candidates for resection of all metastases. All metastases should be treatable by RFA alone or in combination with resection. * Have positive tissue diagnosis by previous resection (less than 6 months) or by radiologic biopsy. * Have clinically suspicious disease defined as a new lesion on chest CT or a suspicious PET scan. * Have RF ablation target lesions of 4 centimeters or less in diameter. Exclusion Criteria: * If the lesion is centrally located, less than 3 centimeters from the hilum. * If the target lesion is greater than 4 centimeters in diameter. * If the lesion is metastatic and the primary site is not controlled. * If extra-thoracic metastatic disease is present. * If there are more than 3 tumors in one lung. * If there are greater than 6 metastatic tumors in total (bilateral). * If it is felt that all metastases cannot be treated by RFA alone or in combination with resection. * If the patient is pregnant or nursing at the time of the procedure. * If the patient has malignant pleural effusion. * If the patient is unwilling or unable to provide consent for the procedure. * If the patient is less than 18 years of age (the short form \[SF\]-36 is not designed for patients less than 18 years of age).

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Hillman Cancer CenterPittsburgh, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 14, 2026. Always confirm current availability with the study team.

View original record ↗